Skip to main content

Table 1 Baseline characteristics of the patients with complete data to perform the final regression analyses shown in Table 2 and the corresponding Additional file 1: Table S1

From: Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD—results from COSYCONET

 

Recently diagnosed mild to moderate COPD, n = 487

GOLD 0–4 n = 1470

Demographics

 Age (years)

64 (58; 70)

65 (59; 70)

 Men (%)

279 (57.3%)

898 (61.1%)

 BMI (kg/m2)

27.1 (24.3; 31.1)

26.6 (23.7; 30.0)

 Current smoker (%)

173 (35.5%)

430 (29.3%)

 Packyears

42 (23; 64)

42 (21; 66)

Comorbidities

 Hypertension (%)

273 (56.1%)

846 (57.6%)

 Diabetes mellitus (%)

73 (15.0%)

205 (13.9%)

 Hyperlipidemia (%)

244 (50.1%)

668 (45.4%)

 Coronary artery disease (%)

79 (16.2%)

249 (16.9%)

 Heart failure (%)

23 (4.7%)

80 (5.4%)

 History of myocardial infarction (%)

44 (9.0%)

127 (8.6%)

 History of stroke (%)

27 (3.5%)

60 (4.1%)

COPD characteristics

 FEV1% predicted (4)

68.8(59.3; 81.1)

56.0 (42.4; 71.5)

 TLCO % predicted (4)

67.7 (54.8; 80.4)

59.3 (44.0; 73.3)

 SGRQ

33.8 (21.4; 47.4)

39.5 (27.5; 54.6)

 Ankle-brachial index (ABI) ≤ 0.9 (%)

17 (3.5%)

65 (4.4%)

 LVEF (%)

60 (56; 68)

60 (56; 67)

 Moderate exac. in prev. year ≥ 1 (%)

131 (26.9%)

517 (35.2%)

 6-min walk distance (6-MWD) (m)

466 (401; 512)

437 (369; 490)

 Hypoxemia PaO2 < 60 mmHg (%)

68 (14.0%)

267 (18.8%)

 Hypercapnia PaCO2 > 55 mmHg (%)

0 (0%)

2 (0.1%)

 GOLD 0/1/2/3/4 (%)

24.4/14.4/61.2%

13.0/8.4/39.7/31.7/7.1%

 GOLD A/B/E

56.3/16.8/26.9%

42.4/22.6/35.1%

Biomarkers from blood

 Glycated hemoglobin (mmol/mol)

5.80 (5.6; 6.2)

5.8 (5.5; 6.1)

 Creatinine (mg/dL)

0.87 (0.75; 1.02)

0.86 (0.75; 1.00)

 CRP (mg/dL)

0.40 (0.16; 0.63)

0.45 (0,20; 0.68)

 NT-proBNP (pg/mL)

180.8 (35.9; 386.2)

189.3 (33.9; 379.5)

Troponin (pg/mL)

3.7 (2.3; 6.4)

3.7 (2.4; 6.5)

 COPAVP (pmol/L)

5.29 (3.74; 8.20)

5.55 (3.76; 8.68)

 MRproADM (nmol/L)

0.663 (0.566; 0.809)

0.675 (0.571; 0.814)

 MR-proANP (pmol/L)

65.6 (47.0; 91.2)

65.5 (47.5; 93.8)

 Fibrinogen (g/L)

2.40 (1.74; 3.22)

2.44 (1.80; 3.19)

  1. Median values and quartiles (in parentheses) are given, or absolute numbers and percentages (in parentheses, except for GOLD categories for which only percentages are given)
  2. BMI body mass index, FEV1 forced expiratory volume in 1 s, TLCO lung diffusing capacity for carbon monoxide, SGRQ St George’s Respiratory Questionnaire, LVEF left-ventricular ejection fraction from echocardiography, PaO2 and PaCO2 arterial partial pressures of oxygen and carbon dioxide, respectively, from the earlobe, GOLD Global Initiative for Chronic Obstructive Lung Disease, CRP C-reactive protein, NT-proBNP -type natriuretic peptide, COVAP copeptin, MRproADM midregional adrenomedullin, MRproANP midregional pro atrial naturetic peptide
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us